Silo Pharma (Nasdaq: SILO) partnered with Resyca BV to conduct a drug-device study for their lead asset, SPC-15, an...

Silexion Therapeutics (NASDAQ: SLXN) has completed preclinical studies of its RNAi therapeutic candidate, SIL204, in colorectal, lung, and pancreatic...

ABLi Therapeutics recently completed an End of Phase 2 meeting with the FDA to discuss results from their Parkinson’s...

Route 92 Medical announced positive results from its SUMMIT MAX trial of the HiPoint Reperfusion System, including the super-bore...

ZyVersa Therapeutics announced new research supporting the potential of its Inflammasome ASC Inhibitor IC 100 as a disease-modifying treatment...

Galimedix Therapeutics announced published preclinical data on GAL-201, a small molecule drug candidate for Alzheimer’s disease. The data demonstrates...

Tango Therapeutics has initiated a Phase 1/2 clinical trial of TNG456, a brain-penetrant PRMT5 inhibitor, for patients with MTAP-deleted...

Tonix Pharmaceuticals has initiated a Phase 2 trial, called OASIS, to evaluate TNX-102 SL for reducing the severity of...

As GenAI gains traction across life sciences, the conversation is rapidly shifting from potential to practicality. Yet, many organizations...

In this interview, Anca Copaescu, Founder and CEO at Strategikon, explores the complexities of clinical trial management. Anca provides...